U.S. Paper and Forestry Products Stock News

Earlier this month, International Flavors & Fragrances presented at the World Economic Forum Annual Meeting 2026 in Davos, outlining its role in global flavor and fragrance supply chains. Against a backdrop of recent revenue declines and operating margin losses, the company’s visibility on a WEF stage highlights how closely its turnaround is being watched by global business leaders. With improving sentiment around IFF’s restructuring efforts and earnings recovery prospects, we’ll now examine...

Framing Pinnacle Financial Partners after recent performance Pinnacle Financial Partners (PNFP) has drawn fresh attention after a mixed stretch for the stock, with a 1 day decline of 1.2% and a 1 year total return of 22.2%. In this context, investors are weighing the bank's recent revenue of US$1.95b and net income of US$626.67m alongside its current share price of US$95.90 and reported value score of 4. See our latest analysis for Pinnacle Financial Partners. For context, PNFP’s recent 1 day...

Genesis Energy (GEL) drew investor attention after its board declared new quarterly cash distributions, including an increased payout of $0.18 per common unit and $0.9473 per preferred unit, tied to the December 31, 2025 quarter. See our latest analysis for Genesis Energy. The latest distribution decision comes as Genesis Energy’s unit price has moved to US$16.81, with a 7.83% 1 month share price return and a 5.86% year to date share price return. The 1 year total shareholder return of 70.11%...

Nu Holdings (NYSE:NU) has entered a multiyear partnership with the Mercedes AMG PETRONAS Formula 1 Team. The agreement is aimed at increasing Nu’s global brand awareness by tapping into Formula 1’s international fan base. The partnership focuses on Nu’s key markets, where Formula 1 has a strong following, and is expected to run over several seasons. For investors watching NYSE:NU, this move comes as the stock trades around $18.18, with a return of 9.5% over the past week and 47.6% over the...

Why EZCORP (EZPW) Just Caught Investors’ Attention Fresh interest in EZCORP (EZPW) has been driven by its latest earnings report, which topped analysts' consensus estimates, along with research firms maintaining generally positive ratings on the stock. See our latest analysis for EZCORP. That earnings beat and generally positive research coverage have arrived alongside a 90 day share price return of 20.52% and a one year total shareholder return of 73.95%, which suggests momentum has been...

Credit Acceptance (CACC) recently amended its Term ABS 2021-1 facility, extending the $100.0 million asset-backed non-recourse financing to January 18, 2028, and reducing the spread to SOFR plus 140 basis points. See our latest analysis for Credit Acceptance. The financing extension and the planned retirements of the Chief Analytics Officer and Chief Sales Officer come against a mixed backdrop, with a 1-day share price return of 1.69% set against a 90-day share price return decline of 8.34%...

If you are wondering whether Norfolk Southern's current share price still offers value after a strong run in recent years, you are not alone. The stock closed at US$288.26, with a 0.8% decline over the last 7 days, a 0.9% decline over 30 days, but gains of 0.2% year to date, 13.3% over 1 year, 29.6% over 3 years and 33.3% over 5 years. Recent headlines around Norfolk Southern have focused on its operational performance, regulatory attention and the broader discussion around US rail...

MSCI has launched a consultation on reclassifying Greece from Emerging Market to Developed Market status. The consultation seeks feedback from international investors on the potential change to Greece’s market classification. A decision is expected in the coming months, which could influence index composition and fund allocations tied to MSCI benchmarks. For you as an investor looking at MSCI, ticker NYSE:MSCI, this consultation highlights how central the company is to global index...

Why Innoviva (INVA) is drawing fresh attention Innoviva (INVA) is back on investors’ radar after recent share price moves, with the stock last closing at US$19.52. That has many shareholders reassessing how its current valuation lines up with fundamentals. See our latest analysis for Innoviva. The recent pullback, including a 1-day share price return of 0.20% decline and a modest 30-day share price return of 1.41% decline, comes after a stronger 90-day share price return of 10.34% and multi...

What the latest move in DLocal (NasdaqGS:DLO) means for investors DLocal (NasdaqGS:DLO) has drawn investor attention after a recent uptick in the share price, with the stock up 2.4% over the past day and 4.8% across the past week. That short term strength sits alongside a mixed return profile. The stock has gained 4.4% over the past month but declined 5.0% over the past 3 months, which may prompt you to recheck the company’s fundamentals. See our latest analysis for DLocal. With the share...

Atmus Filtration Technologies (ATMU) is back in focus after reporting 10.9% year on year revenue growth and the largest analyst estimates beat in its industry group, including strong EBITDA and adjusted operating income. See our latest analysis for Atmus Filtration Technologies. The recent Q3 beat appears to be feeding into price momentum, with a 30-day share price return of 7.26% and a 90-day share price return of 24.73%. The 1-year total shareholder return of 41.09% points to strong gains...

Regulatory update and why it matters for Capricor investors Capricor Therapeutics (CAPR) shares are in focus after the company reported a new step in the U.S. regulatory process for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA has requested the full Phase 3 HOPE-3 clinical study report and supporting data to address a prior Complete Response Letter, without asking for new clinical trials or additional patient data. See our latest analysis for Capricor...

If you are wondering whether Danaher shares still offer good value at current levels, looking at how the market is pricing the business today can give you useful context before you make your next move. The stock last closed at US$236.71, with returns of 0.3% over 7 days, 2.8% over 30 days, 2.7% year to date, 3.2% over 3 years and 12.9% over 5 years, while the 1 year return was a 4.9% decline. Recent coverage around Danaher has focused on its position as a large healthcare and life sciences...

If you are looking at NuScale Power and wondering whether the current share price gives you good value, you are not alone. This stock often catches the eye of investors who focus on valuation first. The share price sits at US$18.40 after a 23.9% gain over the last 30 days, even though the 7 day return is an 8.9% decline and the 1 year return sits at a 9.2% loss, while the 3 year and 5 year returns are 71.6% and 72.0% respectively. Recent news around NuScale Power has focused on its role in...

Why BioMarin Pharmaceutical Is Back on Investor Radars BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent share price swings, with the stock showing a small move over the past day, a gain over the past week, and declines over the month and past 3 months. See our latest analysis for BioMarin Pharmaceutical. Looking beyond the latest move, BioMarin Pharmaceutical’s 90 day share price return of 6.15% sits against a weaker year to date share price return of 4.49% and a 1 year...

General Dynamics Information Technology, a unit of NYSE:GD, secured a nearly US$1b contract. The contract focuses on modernizing the U.S. Navy’s C5ISR systems. The award centers on improving naval command, control, communications, computers, combat systems, intelligence, surveillance, and reconnaissance capabilities. For you as an investor, this contract highlights how NYSE:GD is positioned within high priority defense programs tied to digital infrastructure and mission systems. C5ISR work...

Acumen Pharmaceuticals recently reported that its Chief Medical Officer and Chief Financial Officer sold shares under pre-arranged trading plans to cover tax obligations from vested restricted stock units, while the company dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for sabirnetug in Alzheimer’s disease. The combination of extending sabirnetug treatment for an additional 52 weeks and sharing fresh clinical research and recruitment insights...

Why investor interest in Patria Investments is picking up now Investor attention around Patria Investments (PAX) has picked up as the firm repeatedly increases its annual fundraising guidance and reports growing capital inflows across private equity, infrastructure, and credit strategies. This backdrop, paired with stronger long term shareholder returns relative to recent month and past 3 months performance, is prompting some investors to take a closer look at how the current share price...

Arthur J. Gallagher, which now carries a market capitalization of about US$64.22 billion, is set to report its December 2025-quarter earnings on January 29, with analysts expecting higher revenue and year-over-year earnings growth as of today. Analysts’ Most Accurate Estimate currently sits above the broader consensus, highlighting how shifting expectations can materially influence sentiment ahead of an earnings release. With recent optimism around earnings expectations, we’ll explore how...

If you are wondering whether Micron Technology's share price still offers value after a strong run, this article will help you frame that question in a clear, practical way. Micron's stock last closed at US$389.09, with returns of 6.6% over 7 days, 36.6% over 30 days, 23.4% year to date, 342.3% over 1 year and a very large gain over 3 years relative to its starting point. These moves have come as Micron has stayed central to the market conversation around memory and AI related demand, which...

If you are wondering whether CRISPR Therapeutics at around US$54.65 offers good value today, it helps to step back from the headlines and look at what the numbers are actually saying. The stock has returned 2.1% over the last 7 days, 1.6% year to date, 30.6% over the past year, 9.4% over 3 years, and has a 67.0% decline over 5 years, a mix that can change how investors view both its potential and its risks. Recent attention on CRISPR Therapeutics has centered on its gene editing pipeline and...

In January 2026, Comstock Inc. and its subsidiary Comstock Metals LLC secured an expandable Ohio site that will serve as a centralized hub for collecting, preparing, storing, and aggregating decommissioned solar panels across Ohio and the broader Midwest, with future plans to build out full recycling and processing capabilities. This move extends Comstock Metals’ national solar panel recycling footprint while supporting zero-landfill, materials-recovery solutions for a wide range of regional...

If you have been wondering whether Marsh & McLennan Companies at about US$183.66 is offering fair value or not, this article walks through what the numbers actually say about the stock. The share price has returned 0.7% over the last week, a 1.8% decline over the last month, 0.7% year to date, and a 16.6% decline over the past year, set against longer term returns of 11.3% over three years and 79.0% over five years. Those mixed returns sit against a backdrop of ongoing interest in large...

What PayPal’s latest moves could mean for investors PayPal Holdings (PYPL) has been beating earnings and revenue expectations recently, while rolling out new services like free DIY tax filing with april and richer digital gift card rewards through Blackhawk Network. See our latest analysis for PayPal Holdings. Despite the product launches and partnerships around tax filing, PYUSD and digital gift cards, recent share price momentum has been weak, with a 30 day share price return of 5.62%...